JSM Activity #92

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2002 Program page


Activity ID:  92
Title
* Issues Relating to Crossover Trials
Date / Time / Room Sponsor Type
08/12/2002
10:30 AM - 12:20 PM
Room: H-Murray Hill Suite B 		Biometrics Section*, Biopharmaceutical Section*, ENAR Topic Contributed
Organizer: Lynn Wei, Merck & Company, Inc.; Xun Chen, Merck Research Laboratories
Chair: Hui Quan, Merck Research Laboratories
Discussant:  
Floor Discussion 12:15 PM
Description

Crossover design is often used in clinical trials including phase I pharmacokinetic trials and other phase trials in chronic disease. This session discusses issues related to design and analysis of cross-over trials and includes 5 presentations by speakers from both academia adn industry. Topics include practical issues in planning crossover trials in drug development, a non-parametric procedure, a more powerful bioequivalence analysis procedure, robustness of estimators, and an automated system for non-statisticians.
  301080  By:  Xun  Chen 10:35 AM 08/12/2002
A Note on ANOVA Assumptions and Robust Analysis for a Crossover Study

  301088  By:  Donghui  Zhang 10:55 AM 08/12/2002
A Highly Automated Crossover Study Analysis System for Non-statisticians

  301120  By:  Stephen J. Senn 11:15 AM 08/12/2002
Practical Issues in Planning Cross-over Trials in Drug Development

  301134  By:  Devan V. Mehrotra 11:35 AM 08/12/2002
A More Powerful Average Bioequivalence Analysis for the 2x2 Crossover

  301149  By:  Francois  Bellavance 11:55 AM 08/12/2002
A Nonparametric Procedure for the Analysis of Balanced Crossover Designs

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002